单流体填充胃内球囊在真实世界人群中安全有效诱导减重
该研究基于8个中心的321例患者数据,评估Orbera胃内球囊在真实临床环境中的安全性、有效性及耐受性。结果显示3、6、9个月总体重减轻分别为8.5%、11.8%、13.3%,早期移除率为16.7%,使用选择性5-羟色胺或5-羟色胺-去甲肾上腺素再摄取抑制剂与6个月前移除风险增加相关(OR 3.92)。
要点
- 3、6、9个月总体重减轻分别为8.5%±4.9%、11.8%±7.5%、13.3%±10%。
- 6个月时88%、62%、31%的患者分别达到5%、10%、15%的体重减轻。
- 早期移除率为16.7%,使用SSRI/SNRI与6个月前移除风险增加相关(OR 3.92)。
核心结论
- 在真实临床人群中,Orbera胃内球囊安全、有效诱导减重并改善肥胖相关合并症。
- 8周前早期移除率在临床试验与真实世界人群间无显著差异,但受药物使用影响。
研究设计与样本
- 上市后监管研究,分析Mayo Clinic数据库8个中心(3个学术中心、5个私立中心,4名外科医生和4名消化内科医生)的数据。
- 最终分析纳入321例患者,平均年龄48.1±11.9岁,80%为女性,基线体重指数37.6±6.9。
- 采用探索性多变量线性和逻辑回归分析识别成功和早期球囊移除的预测因素。
主要发现
- 4例患者在内镜检查时存在放置禁忌症。
- 所有球囊均安全移除,早期移除率(6个月前)为16.7%,移除中位时间为放置后8周(范围1-6个月)。
- 放置球囊时使用选择性5-羟色胺或5-羟色胺-去甲肾上腺素再摄取抑制剂与6个月前移除的 odds 增加相关(OR 3.92;95%CI 1.24-12.41)。
- 3个月总体重减轻8.5%±4.9%(n=204),6个月11.8%±7.5%(n=199),9个月13.3%±10%(n=47)。
- 6个月时,88%、62%、31%的患者分别达到5%、10%、15%的总体重减轻。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The Orbera intragastric balloon (OIB) is a single fluid-filled intragastric balloon approved for the induction of weight loss and treatment of obesity. However, little is known about the effectiveness and safety of the OIB outside clinical trials, and since approval, the Food and Drug Administration has issued warnings to health care providers about risk of balloon hyperinflation requiring early removal, pancreatitis, and death. We analyzed data on patients who have received the OIB since its approval to determine its safety, effectiveness, and tolerance in real-world clinical settings. METHODS: We performed a postregulatory approval study of the safety and efficacy of the OIB, and factors associated with intolerance and response. We collected data from the Mayo Clinic's database of patient demographics, outcomes of OIB placement (weight loss, weight-related comorbidities), technical aspects of insertion and removal, and adverse events associated with the device and/or procedure, from 8 centers (3 academic, 5 private, 4 surgeons, and 4 gastroenterologists). Our final analysis comprised 321 patients (mean age, 48.1 ± 11.9 y; 80% female; baseline body mass index, 37.6 ± 6.9). Exploratory multivariable linear and logistic regression analyses were performed to identify predictors of success and early balloon removal. Primary effectiveness outcomes were percentage of total body weight lost at 3, 6, and 9 months. Primary and secondary safety outcomes were rates of early balloon removal, periprocedural complications, dehydration episodes requiring intravenous infusion, balloon migration, balloon deflation or hyperinflation, pancreatitis, or other complications. RESULTS: Four patients had contraindications for placement at the time of endoscopy. The balloon was safely removed in all instances with an early removal rate (before 6 months) in 16.7% of patients, at a median of 8 weeks after placement (range, 1-6 mo). Use of selective serotonin or serotonin-norepinephrine re-uptake inhibitors at the time of balloon placement was associated with increased odds of removal before 6 months (odds ratio, 3.92; 95% CI, 1.24-12.41). Total body weight lost at 3 months was 8.5% ± 4.9% (n = 204), at 6 months was 11.8% ± 7.5% (n = 199), and at 9 months was 13.3% ± 10% (n = 47). At 6 months, total body weight losses of 5%, 10%, and 15% were achieved by 88%, 62%, and 31% of patients, respectively. Number of follow-up visits and weight loss at 3 months were associated with increased weight loss at 6 months (β = 0.5 and 1.2, respectively) (P < .05). Mean levels of cholesterol, triglycerides, low-density lipoprotein, and hemoglobin A1c, as well as systolic and diastolic blood pressure, were significantly improved at 6 months after OIB placement (P < .05). CONCLUSIONS: In an analysis of a database of patients who received endoscopic placement of the OIB, we found it to be safe, effective at inducing weight loss, and to reduce obesity-related comorbidities in a real-world clinical population. Rates of early removal (before 8 weeks) did not differ significantly between clinical trials and the real-world population, but were affected by use of medications.
引用
- Vargas EJ, Pesta CM, Bali A, et al. Single Fluid-Filled Intragastric Balloon Safe and Effective for Inducing Weight Loss in a Real-World Population. Clin Gastroenterol Hepatol. 2018. PMID: 29425781. doi:10.1016/j.cgh.2018.01.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。